valproic acid has been researched along with tamoxifen in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 10 (29.41) | 29.6817 |
| 2010's | 20 (58.82) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Bebchuk, JM; Chen, G; Glitz, D; Hasanat, KA; Manji, HK; Moore, GJ | 1 |
| Basta-Kaim, A; Budziszewska, B; Jaworska-Feil, L; Kubera, M; Lasoń, W; Leśkiewicz, M; Tetich, M | 1 |
| Benes, V; Brand, H; Denger, S; Gannon, F; Ibberson, D; Ivacevic, T; Lin, CY; Liu, ET; Métivier, R; Reid, G | 1 |
| Bader, SE; Hodges-Gallagher, L; Kushner, PJ; Valentine, CD | 1 |
| DiazGranados, N; Zarate, CA | 1 |
| Bandino, A; Bertino, S; Boccuzzi, G; Catalano, MG; Compagnone, A; Costantino, L; De Bortoli, M; Fortunati, N | 1 |
| Biçaku, E; Marchion, DC; Münster, PN; Thomas, S; Thurn, KT | 1 |
| Guo, SW; Liu, X | 1 |
| Artemov, D; Carraway, H; Domek, J; Kato, Y; Kimble, B; Kowalski, J; Lisok, A; Raman, V; van der Groep, P; van Diest, P; Vesuna, F | 1 |
| Amacher, DE; Chalasani, N | 1 |
| Guo, GL; Schumacher, JD | 1 |
| Bouker, KB; Clarke, R; Cook, KL; Cruz, MI; de Assis, S; Hilakivi-Clarke, L; Hu, R; Jin, L; Nguyen, N; Wang, X; Wang, Y; Wärri, A; Wehrenberg, B; Xuan, J; Zhang, X; Zwart, A | 1 |
| Addison, C; Arnaout, A; Dimitroulakos, J; Khouri, L; Li, X; McGarry, S; Nessim, C; Sulaiman, A; Sulaiman, B; Wang, L | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Nomura, I; Okuya, M; Sakuma, K | 1 |
| Cao, D; Hong, Y; Huang, W; Wang, L; Wei, H; Xu, J; Zhang, J | 1 |
9 review(s) available for valproic acid and tamoxifen
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
Topics: Bipolar Disorder; Calcium-Calmodulin-Dependent Protein Kinases; Carbamazepine; Gene Expression; Glycogen Synthase Kinases; Humans; Lithium; Mood Disorders; Protein Kinase C; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tamoxifen; Transcription Factor AP-1; Valproic Acid | 1999 |
A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder.
Topics: Adult; Animals; Antimanic Agents; Bipolar Disorder; Brain; Controlled Clinical Trials as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Therapy, Combination; Drugs, Investigational; Female; Humans; Lithium Carbonate; Male; Protein Kinase C; Tamoxifen; Valproic Acid | 2008 |
Drug-induced hepatic steatosis.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Retroviral Agents; Anticholesteremic Agents; Anticonvulsants; Antineoplastic Agents, Hormonal; Drug Evaluation, Preclinical; Fatty Liver; Humans; Immunosuppressive Agents; Lysosomal Storage Diseases; Methotrexate; Mitochondria, Liver; Phospholipids; Tamoxifen; Valproic Acid | 2014 |
Mechanistic review of drug-induced steatohepatitis.
Topics: Amiodarone; Animals; Camptothecin; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fatty Liver; Hepatocytes; Humans; Irinotecan; Lipid Metabolism; Liver; Methotrexate; Mitochondria, Liver; Organoplatinum Compounds; Oxaliplatin; Perhexiline; Tamoxifen; Tetracycline; Valproic Acid | 2015 |
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Female; Haloperidol; Humans; Lithium; Male; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Tamoxifen; Valproic Acid | 2022 |
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Carbamazepine; Dibenzocycloheptenes; Haloperidol; Humans; Lithium; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Piperazines; Quetiapine Fumarate; Risperidone; Tamoxifen; Thiazoles; Valproic Acid | 2022 |
25 other study(ies) available for valproic acid and tamoxifen
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Mood stabilizers inhibit glucocorticoid receptor function in LMCAT cells.
Topics: Amphetamine; Animals; Anthracenes; Antimanic Agents; Blotting, Western; Carbamazepine; Cell Line; Cell Survival; Chloramphenicol O-Acetyltransferase; Corticosterone; Dose-Response Relationship, Drug; Flavonoids; Gene Expression Regulation, Enzymologic; Imidazoles; Indoles; Inositol; Lithium; Maleimides; Protein Kinase C; Protein Kinase C-alpha; Pyridines; Receptors, Glucocorticoid; Tamoxifen; Tetradecanoylphorbol Acetate; Valproic Acid | 2004 |
Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A.
Topics: Base Sequence; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Enzyme Inhibitors; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Markers; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kinetics; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Transcription, Genetic; Valproic Acid | 2005 |
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Topics: Aromatase; Breast Neoplasms; Cell Line; Cell Proliferation; Enzyme Inhibitors; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Receptor, ErbB-2; Sensitivity and Specificity; Tamoxifen; Uterus; Valproic Acid | 2007 |
Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; Tamoxifen; Transcription, Genetic; Valproic Acid | 2010 |
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Gene Expression; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Membrane Proteins; Microtubule-Associated Proteins; Panobinostat; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Signal Transduction; Tamoxifen; Valproic Acid; Vorinostat | 2011 |
Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis.
Topics: Analgesics, Non-Narcotic; Animals; Animals, Newborn; Endometriosis; Female; Hyperalgesia; Mice; Mice, Inbred ICR; Myometrium; Random Allocation; Tamoxifen; Tocolytic Agents; Valproic Acid | 2011 |
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Breast Neoplasms; Capillary Permeability; Cell Line, Tumor; Chromatin; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Down-Regulation; Drug Resistance, Neoplasm; E-Box Elements; Estrogen Receptor alpha; Estrogens; Female; Histone Deacetylase 1; Histones; Humans; Mice; Nuclear Proteins; Promoter Regions, Genetic; Protein Transport; RNA, Small Interfering; Tamoxifen; Twist-Related Protein 1; Valproic Acid | 2012 |
Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenovirus E1A Proteins; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Ethinyl Estradiol; Female; Galectin 3; Gene Expression; Gene Silencing; Histocompatibility Antigens Class I; Humans; Hydralazine; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Mammary Neoplasms, Experimental; Neoplasm Recurrence, Local; Pregnancy; Prenatal Exposure Delayed Effects; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Trans-Activators; Valproic Acid | 2017 |
Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition.
Topics: Antineoplastic Agents; beta Catenin; CD24 Antigen; Cell Line; Cell Proliferation; Epithelial Cells; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Receptor, ErbB-2; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tamoxifen; Triple Negative Breast Neoplasms; Valproic Acid; Wnt Proteins | 2016 |